XL388 - mTOR 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEXL388Cat. No.: HY-13806CAS No.: 1251156-08-7分式: CHFNOS分量: 455.5作靶點(diǎn): mTOR作通路: PI3K/Akt/mTOR儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (109.77 mM; Need ultrasonic)Mass Solvent1

2、mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.1954 mL 10.9769 mL 21.9539 mL5 mM 0.4391 mL 2.1954 mL 4.3908 mL10 mM 0.2195 mL 1.0977 mL 2.1954 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終

3、溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.49 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.49 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 XL388種效的 ATP 競(jìng)爭(zhēng)性 mTO

4、R 抑制劑，IC50 為 9.9 nM。XL388 同時(shí)抑制 mTORC1 和 mTORC2。IC50 & Target mTOR mTORC1 mTORC2 DNA-PK9.9 nM (IC50) 8.831 M (IC50)體外研究 XL388 (Compound 28) also inhibits DNA-PK with an IC50 of 8.831 M. XL388 inhibits cellularphosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S4

5、73)substrates. XL388 acts in an ATP-competitive manner, with a linear increase in IC50 values with increasingATP concentration 1. XL388 shows a dose-dependent effect in promoting MG-63 cell apoptosis. XL388(100 nM) induces apoptosis in other two OS cell lines (U2OS and SaOs-2), but not in non-cancer

6、ous MC3T3-E1 cells. XL388 potently inhibits activation of both mTORC1 and mTORC2 in MG-63 cells. The effect ofXL388 on mTORC1/2 activation is again dose-dependent. Further, mTORC1/2 activation is almost blocked inXL388 (100 nM)-treated U2OS cells, SaOs-2 cells and primary human OS cells 2.體內(nèi)研究 To as

7、sess the pharmacodynamic effects of XL388 (Compound 28) on the mTOR pathway signaling, athymicnude mice bearing PC-3 prostate tumors are dosed orally at 100 mg/kg of XL388. Rapamycin is alsoadministered intraperitoneally at 5 mg/kg as a reference. Plasma and tumor samples are collected at 1, 4, 8,16

8、, 24, and 32 h for XL388 and at 4 h for Rapamycin after dosing and homogenized with buffer. Tumorlysates from each animal (n=5) are then pooled for each group and analyzed by immunoblot for levels ofphosphorylated p70S6K, S6, 4E-BP1, and AKT. XL388 has moderate terminal elimination half-life (t1/2=1

9、.35h, 0.45 h, 6.11 h and 0.86 h for mouse (10 mg/kg, iv), rat (3 mg/kg, iv), dog (3 mg/kg, iv), monkey (3 mg/kg,iv) 1.PROTOCOLKinase Assay 1 The measurement of mTOR enzyme activity is performed in an ELISA format following the phosphorylationof 4E-BP1 protein. All experiments are performed in the 38

10、4-well format. Generally, 0.5 L of DMSOcontaining varying concentrations of the test compound is mixed with 15 L of the enzyme solution. Kinasereactions are initiated with the addition of 15 L of a solution containing the substrate. The assay conditionsare as follows: 0.2 nM mTOR, 10 M ATP, and 50 n

11、M NHis-tagged 4E-BP1 in 20 mM Hepes, pH 7.2, 1 mMDTT, 50 mM NaCl, 10 mM MnCl2, 0.02 mg/mL BSA, 0.01% CHAPS, 50 mM -glycerophophate. Followingan incubation of 120 min at ambient temperature, 20 L of the reaction mixture is transferred to a Ni-chelate-coated 384-well plate. The binding step of the 4E-

12、BP1 protein proceeded for 60 min, followed by washingfour times each with 50 L of Tris-buffered saline solution (TBS). Anti-phospho-4E-BP1 rabbitimmunoglobulin G (IgG; 20 L, 1:5000) in 5% BSA-TBST (0.2% Tween-20 in TBS) is added, and the reactionmixuture is further incubated for 60 min. Incubation w

13、ith a secondary horseradish peroxidase (HRP)-taggedanti-IgG is similarly performed after the primary antibody is washed off (four washes of 50 L). Following thefinal wash step with TBST, 20 L of SuperSignal ELISA Femto is added and the luminescence measuredusing an EnVision plate reader. Data are re

14、ported as the mean (n2) 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 2 U2OS, SaOs-2 and MG-63 OS cell lines as well as the murine calvaria-derived osteoblastic MC3T3-E1 cellsare maintained and culture. The OB-6 human osteoblastic cells a

15、re cultured. For primary culture of murine2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEosteoblasts, the trimmed calvariae of neonatal mice are digested with 0.1% collagenase I and 0.25%dispase. The resolving cell suspensions are neutralized with complete culture medium and are filtered. Thecalva

16、rial osteoblasts are then resuspended in 10 mL -MEM containing 15% FBS, and are cultured. Cells(5104/well) are suspended in 1 mL of DMEM with 1% agar, 10 % FBS and with indicated XL388 (5, 25, 100and 200nM) treatment. The cell suspension is then added on top of a pre-solidified 1% agar in a 100 mmcu

17、lture dish. The drug containing medium is refreshed every 2 days. After 10-day incubation, the number ofremaining colonies are stained and manually counted 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice, Rats, Dogs and Monkeys 1Administra

18、tion 1 Pharmacokinetic studies of XL388 are determined in female athymic nude mice, female CD rats, male beagledogs, and male cynomolgus monkeys. XL388 is administered intravenously and by oral gavage at 10 mg/kgas a solution formulated in EPW (5% ethanol/45% PEG400/water+1:2 HCl (m/m) to mice, 3 mg

19、/kg as asolution formulated in EPW (5% ethanol/45% PEG400/water+1:2 HCl (m/m) to CD rats and male beagledogs, and 3 mg/kg as a solution formulated in EPW (5% ethanol/45% PEG400/water+1:1.5 HCl (m/m) tomale cynomolgus monkeys. The plasma levels of XL388 are monitored over a 24 h period.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Oncotarget. 2017 May 2;8(18):30151-30161. Oncotarget. 2016 Aug 2;7(31):49527-49